However, based on current literature, a panel with the following genes will most likely be informative in clinical assessment for most of the myeloid neoplasms: FLT3, NPM1, CEBPA, TP53, IDH1/2, DNMT3A, TET2, CSF3R, SRSF2, KIT, NRAS, RUNX1, WT1, ASXL1, SF3B1 for AML; NRAS, KRAS, IDH1/2, TET2, EZH2, ASXL1, RUNX1, TP53, DNMT3A, SF3B1, U2AF1, ETV6 for MDS; JAK2, CALR, MPL, IDH1/2, ASXL1, TET2, EZH2, SRSF2, SF3B1, TP53 for MPN; TET2, SRSF2, ASXL1, RUNX1, NRAS, TP53 for CMML; SF3B1 for MD/MPN RS-T; CSF3R for CNL, SETBP1 for
aCML, KIT (D816V) for mast cell disease.
A 2013 analysis of exome sequences from 8
aCML cases led to the identification of recurrent SETBP1 somatic mutations; then targeted resequencing demonstrated the SETBP1 mutations were present in 24.3% of 70 patients with
aCML, as well as in the closely related disorders unclassified MDS/ MPN (3/30, 10%) and chronic myelomonocytic leukemia (CMML; 3/82, 4%), and in one of four cases of chronic neutrophilic leukemia (CNL) (2).
All PGI compilers and tools feature full native support for OpenMP parallel programming extensions in Fortran, C, and C++; full support for 64-bit addressing; native integrated scalar and vector SSE/SSE2 code generation; and a bundled version of the
ACML 2.5 library of highly optimized numeric functions for mathematical, engineering, scientific, and financial applications.
Version 5.2 includes full support for all Fortran 95 extensions in PGF90; full native support for OpenMP parallel programming extensions in Fortran, C, and C++; full support for the X86-64 application binary interface (ABI) medium-memory model allowing application data sets and data objects larger than 2 GBytes; native integrated scalar and vector SSE/SSE2 code generation; and a bundled version of the
ACML 2.0 library of highly optimized numeric functions for mathematical, engineering, scientific, and financial applications.